Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 44 pages report, published by Global Markets Direct

Keywords : Non-Small Cell Lung Carcinoma Therapeutic Products under Development, Key Players in Non-Small Cell Lung Carcinoma Therapeutics, Non-Small Cell Lung Carcinoma Pipeline Overview, Non-Small Cell Lung Carcinoma Pipeline, Non-Small Cell Lung Carcinoma Pipeline Assessment

Report ThumbnailSeptember-2013
Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Carcinoma. Non-Small Cell Lung Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Non-Small Cell Lung Carcinoma.
- A review of the Non-Small Cell Lung Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non-Small Cell Lung Carcinoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Carcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Non-Small Cell Lung Carcinoma, H2 2013 7
  • Products under Development for Non-Small Cell Lung Carcinoma - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Non-Small Cell Lung Carcinoma, H2 2013 7
  • Products under Development for Non-Small Cell Lung Carcinoma - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Genentech, Inc., H2 2013 16
  • Cancer Research Technology Limited, H2 2013 17
  • CureVac GmbH, H2 2013 18
  • Axelar AB, H2 2013 19
  • ImmunoFrontier, Inc., H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Non-Small Cell Lung Carcinoma Therapeutics - Drug Profile Updates 37
  • Non-Small Cell Lung Carcinoma Therapeutics - Discontinued Products 39
  • Non-Small Cell Lung Carcinoma Therapeutics - Dormant Products 40
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Non-Small Cell Lung Carcinoma Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Non-Small Cell Lung Carcinoma 7
  • Non-Small Cell Lung Carcinoma Therapeutics under Development by Companies 9
  • Non-Small Cell Lung Carcinoma Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Non-Small Cell Lung Carcinoma Therapeutics - Products under Development by Companies 14
  • Non-Small Cell Lung Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Non-Small Cell Lung Carcinoma Therapeutics Development 16
  • Genentech, Inc. 16
  • Cancer Research Technology Limited 17
  • CureVac GmbH 18
  • Axelar AB 19
  • ImmunoFrontier, Inc. 20
  • Non-Small Cell Lung Carcinoma - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • AXL-1717 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • CHP-MAGE-A4 Vaccine - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • diaziquone - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Revercom - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Drug Targeting Pan-PIM Kinase - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Drugs Targeting RAS Mutant Tumours - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • BV-6 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • SIMM-559 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • CV-9202 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • Non-Small Cell Lung Carcinoma Therapeutics - Drug Profile Updates 37
  • Non-Small Cell Lung Carcinoma Therapeutics - Discontinued Products 39
  • Non-Small Cell Lung Carcinoma Therapeutics - Dormant Products 40
  • Non-Small Cell Lung Carcinoma - Product Development Milestones 41
  • Featured News & Press Releases 41
  • Aug 07, 2013: Interim Results of the GALAXY-1 Trial to be Presented at Best of ASCO 41
  • Aug 24, 2012: US Court Of Appeals Upholds Validity Of Lilly's Alimta Compound Patent 41
  • Jun 04, 2012: Xcovery Presents Phase I Clinical Results Of X-82 At ASCO 2012 Annual Meeting 41
  • Appendix 43
  • Methodology 43
  • Coverage 43
  • Secondary Research 43
  • Primary Research 43
  • Expert Panel Validation 43
  • Contact Us 44
  • Disclaimer 44

Please select a license type

Share

Related Products

Global Markets DirectNon-Small Cell Lung Carcinoma - Pipeline Review, H2 2013Product ThumbnailNon-Small Cell Lung Carcinoma - Pipeline Review, H2 2013, Industry ReportProduct #: 113329
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved